SUBSCRIBE
SUBSCRIBE
News   Policy

U.S. FDA Looks At Anemia Drugs, Cancer Risks

October 19, 2005 | 
1 min read

U.S. regulators are considering whether two anemia-fighting drugs, often given to cancer patients, may in some cases stimulate tumor growth, a question raised by studies of similar products sold in Europe.

Regulatory
Amgen Johnson & Johnson Family of Companies Food and Drug Administration (FDA) Roche
MORE ON THIS TOPIC
Handshake of man and robot. Modern technologies. Art collage.
Artificial intelligence
Amid Layoffs, Delays, FDA Turns to AI for Speedy Reviews
May 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Trendy halftone collage. A hand holds a ringing alarm clock. Time, hurry up. Vector business concepts for graphic and web design, marketing and print materials, social media. Vector illustration
Regulatory
FDA Delays Continue as Regulator Misses Review Date for GSK’s Nucala
May 9, 2025
 · 
2 min read
 · 
Tristan Manalac
illustration of the ship in the storm, gigantic waves
Special edition
Deep Dive: Biopharma In Turmoil As Peter Marks Forced Out of FDA
May 9, 2025
 · 
2 min read
 · 
Annalee Armstrong
Illustration showing businessman avoiding potholes on way to goal
Job Trends
Job Market Woes: More Funding, Stability Needed for Turnaround
May 8, 2025
 · 
5 min read
 · 
Angela Gabriel